Keros Therapeutics

KROS

Biotechnology · Healthcare

Price

$10.64

+0.03 (+0.28%)

Market Cap

$340.5M

Exchange

NASDAQ

Winston Score

Winston is serious

Mixed quality — meaningful strengths and weaknesses.

Share count rising — dilution

+62.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 23.3M (2021) → 37.9M (2025)

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patie

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-87.3% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+24.6% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$130M/ year

↓ Declining (-25% vs prior year)

53.1% of revenue

3.0x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

7.7%ownership

Insiders own a meaningful stake in the company

Cash Runway

~3 years

$287M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

$287M cash & investments at current burn rate

Revenue declining

Keros Therapeutics's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

-3.9%

Thin — -3.9% gross margin

Operating Margin

-6809.4%

Losing money on operations — -6809.4%

ROCE

-8.6%

Weak — -8.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+6775.0%

Fast-growing sales (6775.0% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

124%

Turns 124% of profit into real cash

FCF Margin

43.4%

Converts sales into free cash efficiently (43.4%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.01

Conservative — low debt load (0.01)

Interest Cover

100.00x

—

Comfortably covers interest (100.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

5.7x

Attractive valuation — P/E 5.7

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial